MEI Pharma http://investor.meipharma.com/ MEI Pharma Promotes David M. Urso to Chief Operating Officer http://investor.meipharma.com/2018-07-16-MEI-Pharma-Promotes-David-M-Urso-to-Chief-Operating-Officer Mon, 16 Jul 2018 05:00:00 -0700 http://investor.meipharma.com/2018-07-16-MEI-Pharma-Promotes-David-M-Urso-to-Chief-Operating-Officer MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress http://investor.meipharma.com/2018-06-15-MEI-Pharma-Presents-Clinical-Data-on-ME-401-at-the-European-Hematology-Association-Congress --Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end-- Fri, 15 Jun 2018 05:00:00 -0700 http://investor.meipharma.com/2018-06-15-MEI-Pharma-Presents-Clinical-Data-on-ME-401-at-the-European-Hematology-Association-Congress MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting http://investor.meipharma.com/2018-06-04-MEI-Pharma-Presents-Phase-1b-Clinical-Data-for-ME-401-in-Patients-with-Indolent-B-Cell-Malignancies-at-the-2018-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting -- 90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies -- Mon, 04 Jun 2018 05:01:00 -0700 http://investor.meipharma.com/2018-06-04-MEI-Pharma-Presents-Phase-1b-Clinical-Data-for-ME-401-in-Patients-with-Indolent-B-Cell-Malignancies-at-the-2018-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting http://investor.meipharma.com/2018-06-04-MEI-Pharma-Presents-Clinical-Data-for-ME-344-in-HER2-Negative-Breast-Cancer-Patients-at-the-2018-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting -- ME-344 Mitochondrial Inhibitor in Combination with Avastin Demonstrates Inhibition of Tumor Proliferation in HER2 Negative Breast Cancer Patients -- Mon, 04 Jun 2018 05:00:00 -0700 http://investor.meipharma.com/2018-06-04-MEI-Pharma-Presents-Clinical-Data-for-ME-344-in-HER2-Negative-Breast-Cancer-Patients-at-the-2018-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients http://investor.meipharma.com/2018-05-31-MEI-Pharma-and-Helsinn-Group-Announce-Successful-Interim-Analysis-of-Pracinostat-Azacitidine-Phase-2-Combination-Study-in-Higher-Risk-Myelodysplastic-Syndrome-MDS-Patients -- Predefined Patient Retention Threshold Met: 10% Early Discontinuation Rate Due to Adverse Events Supports Expansion of Patient Enrollment -- Thu, 31 May 2018 05:30:00 -0700 http://investor.meipharma.com/2018-05-31-MEI-Pharma-and-Helsinn-Group-Announce-Successful-Interim-Analysis-of-Pracinostat-Azacitidine-Phase-2-Combination-Study-in-Higher-Risk-Myelodysplastic-Syndrome-MDS-Patients